Centrexion Therapeutics

General Information


We are a late clinical-stage biopharmaceutical company focused on becoming the leader in identifying, developing and commercializing novel, non-opioid and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Pain is a protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses can be mounted. The National Institutes of Health, or NIH, defines chronic pain as pain that persists beyond the normal healing time of an injury or that persists longer than three months. As of 2011, over 40 million adults in the United States and over 1 billion people worldwide suffer from chronic pain each year.

(Note: Centrexion Therapeutics withdrew its IPO registration on May 5, 2021, according to an SEC filing. The IPO was initially filed in October 2018.)

Employees: 24
Founded: 2013
Contact Information
Address 200 State Street, Boston, MA 02109, US
Phone Number (617) 837-6911
Web Address http://www.centrexion.com
View Prospectus: Centrexion Therapeutics
Financial Information
Market Cap
Revenues $047.5 mil (last 12 months)
Net Income $-7.7 mil (last 12 months)
IPO Profile
Symbol CNTX
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $86.3 mil
Manager / Joint Managers Credit Suisse/ SVB Leerink
CO-Managers -
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change